APP下载

美多巴对帕金森患者骨代谢与骨密度的临床观察

2018-06-20常学军

中国现代医生 2018年10期

常学军

[摘要] 目的 觀察美多巴对帕金森患者及正常同龄人骨代谢与骨密度的影响。 方法 选择2016年1月~2017年3月期间在我院就诊的帕金森病(Parkinson's disease,PD)患者45例为PD组及正常同龄人45例为对照组。检测两组受检者治疗前后血钙(Ca)、Ⅰ型前胶原氨基端前肽(PINP)和Ⅰ型胶原交联末端肽(CTX-1)水平,双能X线吸收法(dualenergy X-ray absorptiometry,DXA)检测两组髋部骨密度(BMD)与腰椎骨密度。 结果 PD患者血钙、PINP与25(OH)D3水平均低于对照组,差异有统计学意义(P<0.05),而CTX-1高于对照组(P<0.05);两组人群采用美多巴治疗3、6个月后血钙、PINP与25(OH)D3均较治疗前显著提高(P<0.05);与治疗前相比,血CTX-1水平下降(P<0.05)。PD组经过美多巴治疗6个月后,腰椎及全髋BMD显著提升(P<0.05);对照组经美多巴治疗6个月后,全髋BMD升高(P<0.05);治疗3个月后PD组腰椎及全髋BMD低于对照组(P<0.05);而治疗6个月后两组无差异(P>0.05)。 结论 PD患者的血清钙、Ⅰ型前胶原氨基端前肽(PINP)、25-羟基维生素D3[25(OH)D3]水平均低于对照组;血清Ⅰ型胶原交联末端肽(CTX-1)高于对照组,提示PD患者存在骨代谢异常。美多巴可以改善因PD病导致的骨代谢异常、增加PD患者骨密度,并且对正常人群也有相同作用。

[关键词] 美多巴;帕金森;骨代谢;骨密度

[中图分类号] R742.5 [文献标识码] A [文章编号] 1673-9701(2018)10-0025-03

Clinical observation of madopar on bone metabolism and bone mineral density in patients with Parkinson

CHANG Xuejun

Department of Cerebral Surgery, Guangzhou First People's Hospital, Guangzhou 510180, China

[Abstract] Objective To observe the effect of madopar on bone metabolism and bone mineral density(BMD) in patients with Parkinson and their normal peers. Methods 45 patients with Parkinson's disease(PD) treated in our hospital from January 2016 to March 2017 were selected as PD group and 45 normal peers as control group. The level of blood calcium(Ca), procollagen Ⅰ N-terminal propeptide(PINP) and C-terminal cross-linking telopeptide of type Ⅰ collagen(CTX-1) were measured before and after treatment in two groups. Dualenergy X-ray absorptiometry(DXA) was used to detect the hip BMD and lumbar BMD. Results The levels of serum calcium, PINP and 25(OH)D3 in PD patients were significantly lower than those in the control group(P<0.05), while the level of CTX-1 in the PD patients were higher than the control group(P<0.05). The levels of serum calcium, PINP and 25(OH)D3 increased significantly after 3 and 6 months of treatment with madopar(P<0.05), while the level of blood CTX-1 decreased compared with those before treatment(P<0.05). The BMD of lumbar spine and total hip in PD group increased significantly after 6 months of treatment with madopar(P<0.05). The BMD of total hip increased in control group after 6 months of treatment with madopar(P<0.05). The BMD of lumbar spine and total hip of PD group was lower than that of control group after 3 months of treatment(P<0.05), but there was no significant difference between the two groups after 6 months of treatment(P>0.05). Conclusion The serum levels of calcium, PINP and 25(OH)D3 in PD patients are lower than those in the control group. Serum CTX-1 is higher than the control group, which suggest that patients with PD have abnormal bone metabolism. Madopar could reduce the abnormal bone metabolism due to PD, increase BMD in patients with PD, and also play the same role in general population.

[Key words] Madopar; Parkinson; Bone metabolism; Bone mineral density

帕金森病是一种常见的神经系统变性疾病,老年人多见,平均发病年龄为60岁左右。我国65岁以上人群PD的患病率大约是1.7%,主要临床表现为静止性震颤、肌强直、运动迟缓、姿势和步态异常等[1]。PD病主要是因为大脑黑质细胞合成多巴胺减少,造成多巴胺-乙酰胆碱失衡,表现为乙酰胆碱的兴奋作用。目前治疗PD病最常用的药物有金刚烷胺、安坦、左旋多巴、美多巴(左旋多巴与苄丝肼复方)等。PD病主要的并发症是易跌倒,而老年人多有骨量低下甚至骨质疏松,跌倒后容易发生骨折,严重影响患者的身心健康。且有大量文献报道PD病患者患骨质疏松的比例高于同龄、同性别老年人。现有文献报道美多巴可以治疗骨折延迟愈合[2],但关于美多巴对患者骨代谢及骨密度的影响鲜见报道,因此本研究旨在观察美多巴对帕金森患者以及正常老年人骨代谢及骨密度的影响,现报道如下。……

登录APP查看全文